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Abstract
Introduction Fluorescence guidance is an upcoming method-
ology to improve surgical accuracy. Challenging herein is the
identification of the minimum dose at which the tracer can be
detected with a clinical-grade fluorescence camera. Using a
hybrid tracer such as indocyanine green (ICG)-99mTc-
nanocolloid, it has become possible to determine the accumu-
lation of tracer and correlate this to intraoperative
fluorescence-based identification rates. In the current study,
we determined the lower detection limit of tracer at which
intraoperative fluorescence guidance was still feasible.
Methods Size exclusion chromatography (SEC) provided a
laboratory set-up to analyze the chemical content and to sim-
ulate the migratory behavior of ICG-nanocolloid in tissue.
Tracer accumulation and intraoperative fluorescence detec-
tion findings were derived from a retrospective analysis of
20 head-and-neck melanoma patients, 40 penile and 20
prostate cancer patients scheduled for sentinel node (SN)
biopsy using ICG-99mTc-nanocolloid. In these patients, fol-
lowing tracer injection, single photon emission computed
tomography fused with computed tomography (SPECT/CT)
was used to identify the SN(s). The percentage injected dose
(% ID), the amount of ICG (in nmol), and the concentration
of ICG in the SNs (in μM) was assessed for SNs detected on
SPECT/CT and correlated with the intraoperative fluores-
cence imaging findings.
Results SEC determined that in the hybrid tracer formulation,
41 % (standard deviation: 12 %) of ICG was present in
nanocolloid-bound form. In the SNs detected using fluores-
cence guidance a median of 0.88 % IDwas present, compared
to a median of 0.25 % ID in the non-fluorescent SNs (p-val-
ue < 0.001). The % ID values could be correlated to the
amount ICG in a SN (range: 0.003–10.8 nmol) and the con-
centration of ICG in a SN (range: 0.006–64.6 μM).
Discussion The ability to provide intraoperative fluorescence
guidance is dependent on the amount and concentration of the
fluorescent dye accumulated in the lesion(s) of interest. Our
findings indicate that intraoperative fluorescence detection
with ICG is possible above a μM concentration.
Keywords Sentinel node . SPECT/CT .Multimodal .
Fluorescence-guided surgery .Microdosing
Introduction
(Near-infrared) fluorescence guidance was introduced to im-
prove the intraoperative identification of lesions and to guide
resection of these lesions [1]. This technique has been exten-
sively applied in Japan and provides a high spatial resolution
(down to the sub-micrometer range when dedicated micro-
scopes are used) [2]. Superficially in tissue, it offers an
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increased level of detail compared to the more traditional in-
terventional molecular imaging approaches that are based on
radioactive tracers (centimeter range resolution) [3].
Fluorescence guidance technologies are limited by the strong
attenuation of the signal, meaning the technology loses value
with increasing depth.
To allow fluorescence imaging during the operation, the
fluorescent signal, which directly corresponds to the amount
of accumulated tracer, has to exceed the detection limit of the
imaging system used [4]. To make sure this limit is not an
issue, fluorescent dyes are commonly administered to pa-
tients at high doses, for example indocyanine green (ICG;
administered up to 25 mg) [5], fluorescein (administered up
to 500 mg), or methylene blue (administered up to 10 mg;
this compound comes with an FDA warning) [6]. When
attached to a targeting moiety, the reported doses can still
be considered high. Examples are 0.3 mg/kg folate-FITC
[7], GE-137 up to 0.18 mg/kg [8], and cetuximab-CW800
(up to 62.5 mg/m2) [9]; in a man weighing 75 kg, 62.5 mg/
m2 corresponds to a total dose of approximately 125 mg
(1.7 mg/kg). These latter groups of targeting compounds,
therefore, will come at much higher production costs, espe-
cially when based on antibodies. The key question that needs
to be addressed here is at what minimum dose can fluores-
cent dyes be used for surgical guidance? The answer to this
question, in combination with knowing the binding efficien-
cy of the fluorescence tracer to its target, helps to determine
if future fluorescent probes can be can be applied in patients
using much lower quantities.
The dose applied to a patient drives the ease of translation
and the type of toxicity studies that are required. As a result of
the (in-depth) detection sensitivity of nuclear medicine-based
modalities, the relation between the administered radiotracer
dose and e.g. tumor uptake and in vivo kinetics can be studied
in detail. Moreover, because of their high specificity, resulting
in efficient accumulation at the site of interest and providing
high signal-to-background ratios, imaging can be realized in a
microdosing regime. Inmicrodosing studies <100 µg of a new
drug or imaging agent can be used in a single patient [10], and
extensive expensive toxicity studies can be circumvented. Yet,
this is not applied for fluorescence tracers, where in the most
first-in-human studies, trial-and-error or blood value evalua-
tions have been used for dose optimization [8]. The
microdosing principle is, in part, also driven by economical
aspects; the administered dose will directly relate to costs and
thus is of importance for both business models and future
reimbursement. For routine use of targeted fluorescence
tracers in patients rather than first-in-human trials, it is, there-
fore, crucial to determine the lowest possible dose at which
this technology can be applied.
Hybrid tracers, which contain both a radioactive and a
fluorescent signature, may help to provide insight in the dose
required for efficient intraoperative detection of a fluorescent
signature. Based on the radioactive signal of such tracers,
combined with nuclear imaging, a quantitative evaluation of
the biodistribution can be made. This, in turn, can be directly
related to the intraoperative fluorescence-based detection rate.
A number of hybrid tracers have been studied in humans [3],
and of these ICG-99mTc-nanocolloid has been most extensive-
ly used [11–13]. This tracer was introduced to complement
preoperative sentinel node (SN) mapping and intraoperative
radioactivity-based SN localization with intraoperative near-
infrared fluorescence guidance [11–13]. Because of inter-
patient variations in lymphatic drainage or differences in tis-
sue composition, e.g. obesity, in some cases SNs do not con-
tain tracer, or tracer-containing nodes cannot be detected in-
traoperatively, respectively. Nevertheless, the SNs defined at
single photon emission computed tomography combined with
computed tomography ( SPECT/CT) display a radioactive and
fluorescent signal after more accurate ex vivo evaluation
[11–13]. We thus reasoned that via assessment of the radioac-
tive signature of ICG-99mTc-nanocolloid, it should be possi-
ble to determine the lower detection limit at which fluo-
rescence guidance was still feasible intraoperatively. To
adequately evaluate these aspects, malignancies with both su-
perficial (head-and-neck melanoma, penile cancer; fluores-
cence camera for open surgery) and deep (prostate cancer;
fluorescence laparoscope) lymphatic drainage were included.
Methods
Preparation of the hybrid tracer
For penile cancer patients and head-and-neck melanoma pa-
tients, ICG-99mTc-nanocolloid was prepared as previously de-
scribed [12, 13]. In short, a vial of nanocolloid (GE
Healthcare, Leiderdorp, the Netherlands) (0.5 mg human se-
rum albumin (HSA)) was dissolved in 2 mL saline (0.9 g/L
NaCl) containing freshly eluted pertechnetate (1400 MBq)
resulting in an HSA concentration of 3.76 μM. A vial of
ICG (25 mg) (Pulsion Medical Systems, Feldkirchen,
Germany) was dissolved in 5 mL water for injection. 50 μL
of this ICG solution was added to the 99mTc-nanocolloid
resulting in an ICG concentration of 161 μM. From this vial
approximately 90 MBq±10 % was subtracted and supple-
mented to 0.4 mL with saline. This solution contained
0.49 nmol (32 μg) HSA and 20.8 nmol (16 μg) ICG.
For prostate cancer patients two different tracer formula-
tions were evaluated [11]. The first group received the
ICG-99mTc-nanocolloid prepared according to an earlier used
protocol. In this protocol a vial of nanocolloid (0.5 mg HSA)
was dissolved in 1 mL saline containing freshly eluted
pertechnetate (700 MBq) resulting in an HSA concentration
of 7.52 μM. A vial of ICG (25 mg) was dissolved in 5 mL
water for injection. Of this ICG solution, 50 μL was added to
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the 99mTc-nanocolloid resulting in an ICG concentration of
323 μM. From this vial approximately 250 MBq± 10 %
(0.4 mL) was injected. This solution contained 3.01 nmol
(200 μg) HSA and 129 nmol (100 μg) ICG.
The second group received ICG-99mTc-nanocolloid pre-
pared according to a new protocol. In this protocol a vial of
nanocolloid (0.5 mg HSA) was dissolved in 2 mL saline con-
taining freshly eluted pertechnetate (300 MBq) resulting in an
HSA concentration of 3.76 μM. A vial of ICG (25 mg) was
dissolved in 5 mL water for injection. 50 μL of this ICG
solution was added to the 99mTc-nanocolloid resulting in an
ICG concentration of 161 μM. The complete content of the
prepared vial was injected. This solution contained 7.52 nmol
(500 μg) HSA and 323 nmol (250 μg) ICG.
All tracer preparations were performed under good
manufacturing practice and under supervision of the institu-
tion’s pharmacist.
Size exclusion chromatography
Size exclusion chromatography (SEC) provided a laboratory
set-up able to simulate the migratory behavior of ICG-
nanocolloid in tissue. The small diameter pores in the station-
ary phase mimic the extracellular space in tissue.
ICG-nanocolloid was prepared as described above for the
head-and-neck melanoma and penile cancer and the new for-
mulation used in prostate cancer patients (161 μM ICG), but
without the radioactive pertechnetate addition. Samples of 450
µL were extracted from the vial at 2, 4, 6, and 8 h after prep-
aration. From each sample, 450 µL was loaded onto a size
exclusion column (52×9.6 mm) containing Sephadex G-50
fine (Sigma-Aldrich, St. Louis, Missouri, USA). Gravity was
used to elute the column with saline.
Six fractions of 500 μL were collected over approximately
20 min and diluted with 2 μMHSA to obtain light absorption
below 0.3 at 803 nm. Absorption of each fraction was mea-
sured with a Lambda Bio 20 UV–Vis spectrometer (Perkin
Elmer, Waltham, MA, USA) and the fraction of the total
ICG that co-eluted with nanocolloid in these six fractions
was calculated [14].
Absorption
To determine the presence of different stacked forms of ICG
next to the fluorescent monomer form, UV–Vis absorption
spectra were obtained of the different SEC fractions.
Samples containing the clinical concentration of ICG
(161 μM) were prepared by dissolving ICG in water for in-
jection (5 mg/mL) and subsequent dilution of 50 μL of this
stock in 2 mL water for injection, saline, or in a vial of
nanocolloid dissolved in 2 mL saline. UV–Vis absorption




This retrospective analysis evaluated the fluorescence detec-
tion of SNs in patients that underwent SN biopsy using the
hybrid tracer ICG-99mTc-nanocolloid: 20 patients with mela-
noma in the head-and-neck area, 40 patients with penile can-
cer, and another 20 patients with prostate cancer were includ-
ed. From all patients written informed consent was obtained.
The surgical procedures in melanoma patients and penile
cancer patients were open procedures. The prostatectomies for
prostate cancer were robot-assisted laparoscopic procedures.
All procedures were performed between December 2010 and
June 2013.
Given the intention to identify the lower detection levels
for intraoperative fluorescence guidance, the selection of pa-
tients for this study was biased towards patients with intraop-
erative non-visualization; patients where fluorescence detec-
tion failed during surgery were selectively included.
Injection of the hybrid tracer and preoperative nuclear
imaging
Tracer injection and preoperative SN mapping for head-and-
neck melanoma, penile cancer and prostate cancer have been
described previously [11–13].
In all patient groups image acquisition was performedwith a
SPECT/CT dual-head gamma camera (SymbiaT; Siemens,
Erlangen, Germany) equipped with parallel low energy high
resolution collimators. The following configurations were used
during preoperative imaging: planar lymphoscintigraphy was
acquired at source-to-collimator distances up to 15 cm with an
image acquisition time of 5 min. Non-circular SPECT
(256×256 matrix, 40 frames, 30 s/frame) was performed in
combination with a low-dose CT (130 kV, 40mAs, B30s ker-
nel). Total acquisition time: approximately 14 min including
the low - dose CT. The low-dose CTwas based on 5 mm slices
in penile cancer patients, and on 2 mm slices in head-and-neck
melanoma and prostate cancer patients.
When the circumferential borders of the SNs could be
clearly determined on low-dose CT, the volume of the SNs
was determined. Diameters (a=½ x length, b=½ x width) of
the SN were measured on the low-dose CT, in cms, and the
volume was calculated according to the following formula:
V cm3
  ¼ 4
3
π  að Þ  bð Þ  bð Þ
Image analysis
OsiriX medical imaging software (Pixmeo, Geneva,
Switzerland) was used to measure total pixel values [15].
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Measurements of the injection site and SNs were per-
formed on the SPECT component of the SPECT/CT
scan using a 3D region-growing tool with calculation
of the pixel values. Besides the injection site, and the
SN(s), the rest activity (higher-echelon nodes, spillage)
was calculated. All calculated pixel values were com-
bined resulting in the total pixel value on SPECT/CT.
Liver uptake as a result of shunting during the tracer
administration was not taken into account because it
could not be accurately determined in all patients; in
the head-and-neck and penile cancer patients, the liver
was not present in the field of view when performing
lymphoscintigraphy and SPECT/CT imaging, and in the
prostate cancer patients the liver was only partly present
in the field of view.
Based on the measured total pixel values in the
SPECT scan the percentage of drainage of the injected
dose to an individual SN was calculated using the
following formula:
Drainage to SN %ð Þ
¼ Total pixel value in an individual SN
Total pixel value on SPECT
 100%
Determination nodal ICG accumulation
The SNswere divided into four groups: nodes having received
drainage of 0–1, 1–2, 2–3, and >3 % of the total injected dose
(ID). Based on the known ratio of ICG and 99mTc (see above)
the percentage of 99mTc drainage determined on SPECT was
used to calculate the amount of ICG that accumulated in the
SN using the following formula:
ICG in SN nmolð Þ ¼ Drainage to SN %ð Þ  In jected dose ICG nmolð Þ  Percentage of nanocolloid bound ICG %ð Þ
Here the injected dose of ICG was 20.8 nmol for the
penile cancer and head-and-neck melanoma patients,
129 nmol for the old prostate preparation, and 323 nmol
for the new prostate preparation. The percentage of ICG
bound to nanocolloid after mixing the two was determined
using SEC (see Results).
To determine the concentration of ICG in the SNs, the
uptake of ICG in the SNs was divided by the volume of the
SN (calculated as stated above) using the following formula:
ICG½  in SN nMð Þ ¼ ICG in SN nmolð Þ
Volume of SN cm3ð Þ  1000
Fluorescence detection during surgical procedure
For open procedures (penile cancer, head-and-neck melanoma)
the PhotoDynamicEye (Hamamatsu Photonics KK,
Hamamatsu, Japan) was used as described previously [12, 13].
SN biopsy combined with extended pelvic lymph node dis-
section and prostatectomy was performed robot-assisted (da
Vinci S, Intuitive, Sunnyvale, CA, USA) in prostate cancer
patients. For fluorescence detection in the laparoscopic robotic
setting an additional fluorescence laparoscope (KARL STORZ
GmbH & Co. KG, Tuttlingen, Germany) was used [11].
For localization of the SNs, intermittently the gamma
probe and fluorescence camera were used. To limit the influ-
ence of tissue-based signal attenuation, fluorescence-based
visibility of the SNs (yes/no) was assessed when they were
maximally exposed by the surgeon. This yielded a portion of
SNs that could be resected using intraoperative fluorescence
guidance as well as a portion SNs that contained not enough
signal to allow for intraoperative fluorescence detection.
Statistical analysis
Statistical Package for the Social Sciences (SPSS, IBM, ver-
sion 22) was used to calculate for continuous variables, the
mean or median and interquartile range (IQR; 25–75 %) and
range. For discrete variables, frequencies and percentages are
reported. A Mann–Whitney U test was performed to compare
the means of uptake (% ID) of fluorescent and non-fluorescent
SNs and to compare the means of uptake (% ID) of tumor-
negative and tumor-positive SNs. A comparison of the fluo-
rescence detection rate between tumor-negative SNs and
tumor-positive SNs was performed with a Fisher’s exact test.
Pathology
(Histo-)pathological evaluation of the SNs was performed as
previously described [11–13]. The diameters of the excised
SNs were not defined in the pathological specimens, merely
the tumor status and size of metastases.
Results
Size exclusion chromatography
Preparation of the hybrid tracer ICG-99mTc-nanocolloid, re-
sulted in an ICG to HSA ratio of approximately 43 to 1.
ICG is well soluble in water, but poorly soluble in saline.
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This poor solubility in combination with the tendency of HSA
to bind hydrophobic, aromatic, and fatty acid like compounds,
led to the formation of a non-covalent complex between
nanocolloid and ICG [16, 17].
When ICG-99mTc-nanocolloid is injected in or around
the primary tumor it ends up in the extra-cellular space,
hence the marking of the injection site [18]. From there it
will move, due to the increased interstitial pressure,
through the spaces between the cells and through the ex-
tracellular matrix into the lymphatic ducts (Fig. 1a). A
phantom set-up for this process was provided by SEC
chromatography; the columns used in SEC consist of small
particles (with interstitial spaces) that allow gravity depen-
dent flow wherein different sized compounds are eluted at
different speeds. In this set up the large ICG-nanocolloid
particles eluted first. 41 % (standard deviation: 12 %) of
ICG was present in this fraction, corresponding to 17 ICG
molecules per HSA protein, which is in close agreement
with previous findings [14]. The ICG-nanocolloid frac-
tions remained stable for at least 8 h after preparation.
The SEC experiment also demonstrated that the residual
Boptically silent^ ICG fraction remained present on the
column indicating a small size as well as poor solubility.
Only when the column was washed extensively with
demineralized water or a HSA solution did this fraction
elute from the column. We assume similar behavior for
the injected formulation at the site of injection.
Spectral analysis
ICG diluted in saline (161 μM) without the presence of
nanocolloid showed a strong and broad absorption peak
around 685 nm which is associated with non-fluorescent
(Boptically silent^) H-stacking, J-stacking, and more elab-
orate stacking forms of ICG (Fig. 1c) [19]. The non-
separated ICG-nanocolloid formulation gave a similar ab-
sorption spectrum (Fig. 1c), indicating that the solution
contained a fair amount of stacked ICG. The ICG-
nanocolloid fraction of the SEC purification, however,
displayed an absorption peak correlating to the fluorescent
monomer form of ICG (Fig. 1b and c).
Preoperative imaging
In our clinical dose-evaluation studies we focused on three
patient groups, namely patients with head-and-neck melano-
ma (n=20; 60 SNs), penile cancer (n= 40; 104 SNs) and
prostate cancer (n=20; 65 SNs). Figure 2 provides typical
examples of the pre- and intraoperative imaging findings
when using the hybrid tracer for SN biopsy [11–13].
Intraoperative fluorescence guidance versus hybrid tracer
uptake in the sentinel node(s)
A total of 229 SNs were removed during surgery of which 203
SNs (88.6 %) were identified intraoperatively via their fluo-
rescence signature. The details for the three patient groups are
further specified in Table 1. It must be noted, that in contrast to
our previously published studies [11–13], based on the biased
selection criteria, this study reports a higher non-visualization
rate during the operation. In the overall group, ex vivo analysis
allowed visualization of 97.8 % (224/229) of the SNs via
fluorescence imaging. In some cases the small SNs with small
amounts of tracer were embedded in fatty tissue which
prevented their identification even ex vivo.
SNs were categorized with respect to the % ID uptake in
the SN as defined on preoperative SPECT imaging: 0–1, 1–2,
2–3, and >3 %; of the overall group, 57.2 % of the SNs was
categorized in the 0–1% group (Table 1). In the overall group,
the median hybrid tracer uptake of a via fluorescence imaging
identified SN was 0.88 % ID (IQR 0.25–2.22 % ID), which
Fig. 1 Schematic overview of the size exclusion chromatography
experiments. Phantom set-up to mimic the in vivo drainage of the hybrid
tracer (a). Size exclusion chromatography of the prepared hybrid tracer results
in an ICG-nanocolloid fraction and a fraction of stacked ICG that accumu-
lated on the column (b). Absorption spectra of ICG dissolved in saline, and of
ICG-nanocolloid before and after size exclusion chromatography (c)
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was significantly higher than the median hybrid tracer uptake
in an SN that could not be detected in vivo using fluorescence
imaging, which was 0.25 % ID (IQR 0.13–0.73 % ID)
(Mann–Whitney U test, p-value<0.001). In the 0–1 % ID
drainage range intraoperative fluorescence guidance was least
efficient (Table 1).
The open surgical procedures consisted of two groups. In
the head-and-neck melanoma group, SNs that could be iden-
tified intraoperatively using fluorescence guidance showed a
median hybrid tracer uptake of 0.33 % ID (IQR 0.13–1.31 %
ID) (Table 2). The SNs that could not be identified intraoper-
atively using fluorescence guidance showed a median hybrid
Fig. 2 Typical examples of the
sentinel node biopsy procedure
when using the hybrid approach. In
the first row a head-and-neck
melanoma case is illustrated, in the
second row a penile cancer case is
illustrated and in the third row a
prostate cancer case is illustrated.
From left to right a)
lymphoscintigramwith the location
of the SN(s) (arrows); b) a 3D
volume rendering of the SPECT/
CT (arrows); c) white light imaging
of the SN in vivo; and d) in vivo
fluorescence imaging of the SN.
Fluorescence imaging with the
PDE generates a black-and-white
image, the fluorescence laparo-
scope shows the fluorescence sig-
nal in the SN in blue
Table 1 Drainage % hybrid tracer in sentinel nodes related to the amount of ICG (nmol)
Percentage injected dose
that drained to the SN
Estimated amount
ICG (nmol)
Percentage successful surgical identification
through fluorescence guidance (SN-based)
Percentage of SNs that were missed
intraoperatively using fluorescence guidance (SN-based)
Head-and-neck melanoma patients (60 SNs)
0–1 % ID 0–0.085 80.0 % (32/40) 89 % (8/9)
1–2 % ID 0.085–0.17 92.4 % (12/13) 11 % (1/9)
2–3 % ID 0.17–0.255 100 % (6/6) 0 %
>3 % ID >0.255 100 % (1/1) 0 %
Penile cancer patients (104 SNs)
0–1 % ID 0–0.085 85.1 % (40/47) 88 % (7/8)
1–2 % ID 0.085–0.17 94.8 % (18/19) 12 % (1/8)
2–3 % ID 0.17–0.255 100 % (17/17) 0 %
>3 % ID >0.255 100 % (21/21) 0 %
Prostate cancer patients (10 SNs; old preparation)
0–1 % ID 0–0.53 100 % (7/7) 0 %
1–2 % ID 0.53–1.06 100 % (1/1) 0 %
2–3 % ID 1.06–1.59 0 % (0/1) 100 % (1/1)
>3 % ID >1.59 100 % (1/1) 0 %
Prostate cancer patients (55 SNs; new preparation)
0–1 % ID 0–1.32 81.1 % (30/37) 88 % (7/8)
1–2 % ID 1.32–2.65 88.9 % (8/9) 12 % (1/8)
2–3 % ID 2.65–3.97 100 % (2/2) 0 %
> % ID >3.97 100 % (7/7) 0 %
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tracer uptake of 0.14 % ID (IQR 0.12–0.44 % ID). For the
penile cancer patient group these values were 1.37 % ID (IQR
0.63–2.86 % ID) and 0.38 % ID (IQR 0.13–0.94 % ID), re-
spectively (Table 2).
For the robot-assisted laparoscopic surgery applica-
tion, in the first group (old tracer preparation [11]), the
SNs that could be identified with fluorescence imaging
(9/10 SN) had a median uptake of 0.56 % ID per SN
(IQR 0.17–0.83 % ID), only one SN could not be iden-
tified, giving a somewhat high % ID, with intraoperative
fluorescence imaging (2.30 % ID) (Table 2). In the sec-
ond group (new tracer preparation), which received
ICG-99mTc-nanocolloid in a high dose formulation, the
SNs identified with fluorescence imaging (n= 47) had a
median of 0.70 % ID uptake (IQR 0.18–1.45 % ID)
versus 0.23 % ID (IQR 0.09–0.60 % ID) in the SNs that
could not be identified with fluorescence imaging SN
(n= 8) (Table 2).
It must be noted that the above-mentioned calcula-
tions are likely to overestimate the % ID in the SN
and as such the amount of ICG present in the node.
This is a direct consequence of the inability to measure
the (3D) pixel values in the liver resulting in an
underestimation of the total counts measured in the
SPECT/CT images.
Volumes of the sentinel nodes
The concentration of the hybrid tracer in a SN, and thus the
concentration of ICG, was determined by relating the amount
of ICG in a SN to the volume of that SN derived from the
SPECT/CT images (Table 2). For the SNs located in the neck,
the median size was 0.072 cm3 (IQR 0.033–0.18 cm3). This
value deviates from the 0.50 cm3 and an IQR of 0.36–
0.85 cm3 that was previously reported [20]. A reason for this
difference could be that the size of lymph nodes is very much
dependent on the neck level where they are located [21]. In
the group of penile cancer patients a median of 0.57 cm3
(IQR 0.38–1.12 cm3) was found. In the prostate cancer group,
the measured SNs (n=47) had a median volume of 0.17 cm3
(IQR 0.09–0.27 cm3). The size of the nodes in the penile
cancer group and prostate cancer groups were comparable
with the sizes reported in previous literature of lymph nodes
in the inguinal and pelvic area [22, 23]. The SNs that could
not be measured on CT, overall had a lower % ID uptake of
tracer, suggesting they were small in size.
Table 2 Percentage uptake in sentinel nodes related to the possibility of measurement of sentinel nodes on CT and to intraoperative fluorescence
detection









ICG in SN μM (IQR)
Head-and-neck melanoma
Yes Yes (n= 33) 0.37 (0.13–1.67) 0.031 (0.011–0.142) 0.11 (0.03–0.23) 0.39 (0.15–0.91)
No* (n= 18) 0.33 (0.15–1.10) 0.028 (0.012–0.094) –
No Yes (n= 6) 0.23 (0.08–0.72) 0.020 (0.007–0.061) 0.03 (0.01–0.043) 1.32 (0.28–3.24)
No* (n= 3) 0.14 (0.136) 0.012 (0.012) –
Penile cancer
Yes Yes (n= 90) 1.52 (0.70–2.90) 0.129 (0.060–0.247) 0.57 (0.36–1.12) 0.24 (0.08–0.48)
No* (n= 6) 0.55 (0.20–1.07) 0.047 (0.017–0.910)
No Yes (n= 8) 0.38 (0.13–0.94) 0.032 (0.011–0.080) 0.64 (0.47–1.30) 0.08 (0.019–0.24)
No* (n= 0) – – –
Prostate cancer, old preparation
Yes Yes (n= 5) 0.57 (0.44–2.10) 0.048 (0.037–0.179) 0.17 (0.08–0.86) 1.74 (1.01–4.52)
No* (n= 4) 0.17 (0.07–0.87) 0.090 (0.037–0.46) –
No Yes (n= 1) 2.30 (2.30) 1.22 (1.22) 0.24 5.16
No* (n= 0) – – –
Prostate cancer, new preparation
Yes Yes (n= 36) 0.55 (0.14–1.34) 0.417 (0.185–1.769) 0.17 (0.09–0.32) 2.86 (1.27–15.62)
No* (n= 11) 0.87 (0.63–3.15) 1.148 (0.832–4.158) –
No Yes (n= 5) 0.29 (0.14–0.54) 0.383 (0.184–0.71) 0.14 (0.09–0.23) 2.44 (1.79–3.87)
No* (n= 3) 0.08 0.106 –
* The inability to perform the required volumetric measurements in the low-dose CT depended mostly on the size of the SNs and the poor quality of the
images. CT computed tomography, ID injected dose, IQR interquartile range, SN sentinel node, ICG indocyanine green
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Amount of ICG in quantity and concentration in relation
to intraoperative fluorescence-based detectability
A clear relation was found between the detection rate of the
SNs by fluorescence imaging and the hybrid tracer uptake (in
% ID and amount of ICG; Fig. 3a and b). However, when the
detection rate was related to the ICG concentration, defined
using low-dose CT-derived SN volumes, the relation was not
clear (Fig. 3c).
In head-and-neck melanoma, with the smallest SNs, the
concentration of ICG in the SNs that were detected by fluo-
rescence imaging was similar compared to the SNs that were
not detected by fluorescence imaging (median 0.39 μM vs.
1.32 μM; Table 2 and Fig. 3). In penile cancer patients the
di fference was more dis t inc t , showing a higher
ICG concentration in SNs that could be detected intraopera-
tively compared to those that could not be detected intraoper-
atively via fluorescence imaging (median 0.24 μM, vs.
median 0.08 μM, respectively; Table 2 and Fig. 3). In prostate
cancer patients injected with the old and new tracer prepara-
tion, the median concentration of intraoperatively non-
detectable SNs was 5.16 and 2.44 μM, versus 1.74 and
2.86 μM for the SNs that could be detected via fluorescence
imaging, respectively (Table 2 and Fig. 3).
Fig. 3 Boxplots of intraoperative fluorescence detection versus % ID,
amount of ICG in nmol and the concentration indocyanine green in the
sentinel nodes. a % ID in relation to the intraoperative fluorescence
detection; b The amount of ICG (nmol) in relation to the intraoperative
fluorescence detection; and c The concentration of ICG (μM) in relation
to the fluorescence detection
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The lowest ICG concentration in the SN of which intraop-
erative fluorescence detection was possible, was 0.006 μM.
This was observed in a penile cancer patient.
Pathology
In the total group, 15 patients were tumor-positive (six head-
and-neck patients, five penile cancer patients, and four pros-
tate cancer patients) with a total of 24 tumor-positive SNs.
The % ID uptake of the tumor-positive SNs on SPECTwas
lower compared to the non-tumor positive SNs, with a median
uptake 0.26 % ID (IQR 0.13–1.04 %) and median uptake
0.86 % ID (IQR 0.24–2.08 %), respectively (Mann–Whitney
U test, p-value 0.036). This, however, did not influence the
intraoperative fluorescence detection rate; 83.3 % (20/24) ver-
sus 89.3 % (183/205) for tumor-postive and tumor-negative
SNs, respectively (Fisher’s exact test, p-value 0.492).
Discussion
The dose at which fluorescent dyes can be identified during
surgery is an important factor for future translation and appli-
cation of tracers that enable fluorescence -guided surgery. The
clinical use of the hybrid tracer ICG-99mTc-nanocolloid pro-
vided a unique opportunity to correlate hybrid tracer uptake in
SNs based on SPECT/CT imaging measurements (99mTc-la-
bel) to the intraoperative fluorescence detection rate (ICG-la-
bel). From this analysis the lower detection limit of tracer at
which fluorescence guidance was still feasible could be esti-
mated. This limit was found to be at an μM concentration
level (Table 2).
SEC experiments enabled us to relate the uptake of injected
dose defined on SPECT to the amount of ICG that drained in
the form of ICG-99mTc-nanocolloid. One critical observation
herein is that the portion of non-colloidal bound ICG
Bstacked^ in the formulation used, forming an optically silent
dye deposit that could only dissolve slowly over time and after
extensive washing. In this and other clinical trials using
ICG-99mTc-nanoclloid (current experience in over 600 pa-
tients), however, we did not observe background signal from
Bfree^ ICG, and ex vivo we found a good correlation between
the presence of radioactivity and fluorescence in the SNs
[11–13]. We do want to point out that SEC experiments were
used to simulate and approximate the behavior of ICG-
nanocolloid in human tissue in its most basic form. This ex-
periment does not represent the full complexity of the in vivo
situation, e.g. tissue heterogeneity or the presence of compet-
ing proteins, but merely showed the difference in transport for
the different components present in the tracer without such
effects present. Nevertheless, there appears to be a good con-
currence between the basic SEC findings and the findings
observed in patients.
The % ID uptake of ICG-99mTc-nanocolloid in the SNs,
and the volume of the SNs, allowed us to directly relate the
intraoperative fluorescence imaging-based identification of
SNs to the amount and/or the concentration of ICG. From
this we were able to determine the lower detection fluores-
cence limit at which ICG provided surgical guidance. In
general , when a SN is covered by (fat ty) t issue
fluorescence-based detection is hindered significantly [1].
To minimize the influence of this important dimension in
the analysis, the surgeons involved in this study always
tried to remove the overlaying tissue, prior to analyzing
the fluorescent content of the SN. Obviously, this does
not exclude tissue attenuation by the node itself. When
fluorescence could not be used to guide the surgeon during
exploration, radioguidance was used to determine the exact
location of the SN.
In our study groups the median hybrid tracer uptake in
the SNs was 0.82 % ID. For the SNs visualized by fluores-
cence imaging, the median injected dose was slightly
higher, namely 0.88 % ID (IQR 0.25–2.22 % ID). For the
SNs that could not be intraoperatively identified using
fluorescence guidance, the median was found 0.25 % ID
(IQR 0.13–0.73 % ID) (p-value < 0.001). In a sub-analysis
comparing the uptake % ID in tumor-negative and tumor-
positive SNs, the latter showed lower uptake (p-value
0.036), but this did not influence fluorescence imaging-
based detection in vivo. These findings are in line with
previous reports showing tracer uptake in SNs containing
macrometastases (≤14 mm) [13].
The tracer administration could not be accurately deter-
mined in all patients. In a prospective trial this shortcoming
may be compensated by using a calibrated external reference
99mTc-source in the same field of view as the SNs. In this
study the measured volume on the low-dose CT was used to
calculate the volumes of the SNs. A more accurate calculation
of the nodal volumes could be realized using, e.g. diagnostic
CT or more advanced image processing/segmentation [24].
Alternatively, the weight and volume of the individual
resected SNs could be defined at pathology. Unfortunately,
both do not (yet) seem to be feasible in clinical routine.
The findings of the current study underline that there is
a clear relation between the amount of ICG in the SNs and
their detectability via fluorescence imaging in vivo. Hence,
efficiency of tracer drainage identified using preoperative
imaging may be predictive for the success of fluorescence-
guided surgery; fluorescence examination of the surgical
field should be more meticulous when the drainage is rel-
atively low. We thus argue that the ability to assess the
tracer-binding efficacy prior to surgery is a critical compo-
nent in planning such interventions. It will help prevent
timely and unnecessary surgical explorations towards fluo-
rescent signals that can or cannot be detected during the
operation [25].
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To verify if a microdosing principle is within reach for
fluorescence-based surgical guidance, one should estimate
which part of the injected dosage can accumulate in the
targeted lesions. A recent study of Herrmann et al. described
that for the tumor-targeted tracer 68Ga-pentixafor, up to
0.30 % ID reached the targeted lesions [26]. If we use
0.30 % ID as representative uptake for a high affinity tracer,
this would mean that intravenous administration of 100 mg
[10] of a targeted tracer with a molecular weight of 3.3 kDa
could yield a concentration of 0.09 μM in a lesion of 1 cm3. In
this study ICG in SNs was detected in a concentration range of
0.006–64.61 μMwith a median volume of <1 cm3. Combined
this suggests it is legitimate to assume that a well-designed
and high-affinity receptor-targeted fluorescent tracer can be
applied in a microdosing principle similar to what is standard
for radiotracers. The assumption that optical imaging can be
effective at lower tracer doses is also in line with recent clin-
ical reports that indicate in vivo Cerenkov imaging is feasible
using standard PET-tracer formulations [27, 28]. Given the
constant technical improvements that are being made in cam-
era systems [11], one may assume that the sensitivity of fluo-
rescence guidance will even improve further in the future. The
same will be true if the signal intensity of the fluorescent dyes
can be improved.
Conclusion
For the first time we estimated the minimum amount of ICG in
SNs (>0.003 nmol or >0.006μM level) necessary to achieve a
fluorescent signal suitable for intraoperative guidance. In ad-
dition our results suggest that ICG and perhaps other
fluorescent-tracers can be applied on the basis of the
microdosing concept.
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